Intuitive Surgical (NASDAQ:ISRG) Stock Price Down 0.6% After Insider Selling

Intuitive Surgical, Inc. (NASDAQ:ISRG)’s stock price was down 0.6% on Tuesday following insider selling activity. The company traded as low as $589.00 and last traded at $592.23. Approximately 187,308 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 1,792,521 shares. The stock had previously closed at $595.70.

Specifically, EVP Myriam Curet sold 408 shares of Intuitive Surgical stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total transaction of $240,618.00. Following the completion of the transaction, the executive vice president now owns 353 shares of the company’s stock, valued at $208,181.75. The trade was a 53.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jamie Samath sold 269 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $590.00, for a total transaction of $158,710.00. Following the completion of the sale, the chief financial officer now directly owns 3,282 shares in the company, valued at approximately $1,936,380. The trade was a 7.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Jefferies Financial Group upped their target price on shares of Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. Bernstein Bank boosted their price target on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. Morgan Stanley upgraded Intuitive Surgical from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $522.00 to $650.00 in a research report on Monday, December 2nd. Robert W. Baird boosted their target price on Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Truist Financial raised their price target on Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $613.10.

Intuitive Surgical Stock Down 0.3 %

The firm’s 50-day simple moving average is $556.91 and its 200-day simple moving average is $516.98. The firm has a market capitalization of $210.01 billion, a PE ratio of 91.98, a price-to-earnings-growth ratio of 5.67 and a beta of 1.39.

Institutional Investors Weigh In On Intuitive Surgical

Institutional investors have recently bought and sold shares of the stock. Atala Financial Inc bought a new stake in Intuitive Surgical in the fourth quarter valued at approximately $25,000. Berbice Capital Management LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter worth $26,000. BankPlus Trust Department bought a new stake in Intuitive Surgical during the 4th quarter valued at $28,000. Godsey & Gibb Inc. boosted its position in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares during the period. Finally, Summit Securities Group LLC bought a new stake in Intuitive Surgical in the 4th quarter worth $30,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.